Pacific Biosciences Of California (PACB) EPS (Diluted) Growth (1y) (2015 - 2026)
Pacific Biosciences Of California (PACB) EPS (Diluted) Growth (1y) (2015 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 201.40 Bn | 194.75 Bn | 6.27 Bn | -18.71% |
| 2 | Stryker | 122.29 Bn | 119.41 Bn | 3.81 Bn | 13.88% |
| 3 | Medtronic | 105.01 Bn | 96.40 Bn | 6.41 Bn | 18.72% |
| 4 | Boston Scientific | 64.81 Bn | 63.59 Bn | 3.61 Bn | 98.71% |
| 5 | Edwards Lifesciences | 55.28 Bn | 51.60 Bn | 1.29 Bn | - |
| 6 | Dexcom | 29.06 Bn | 27.94 Bn | 750.30 Mn | 95.96% |
| 7 | Koninklijke Philips | 29.02 Bn | 25.93 Bn | 2.07 Bn | 114.19% |
| 8 | GE HealthCare Technologies | 28.27 Bn | 26.20 Bn | 1.98 Bn | -29.80% |
| 9 | Smith & Nephew | 25.80 Bn | 25.22 Bn | - | - |
| 10 | Pacific Biosciences Of California | 428.15 Mn | 152.18 Mn | 12.84 Mn | 98.11% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 98.11% |
| Dec 31, 2025 | -1,736.89% |
| Sep 30, 2025 | 43.23% |
| Jun 30, 2025 | 78.05% |
| Mar 31, 2025 | -394.92% |
| Dec 31, 2024 | 102.54% |
| Sep 30, 2024 | 15.15% |
| Jun 30, 2024 | -127.86% |
| Mar 31, 2024 | 20.25% |
| Dec 31, 2023 | 13.95% |
| Sep 30, 2023 | 23.30% |
| Jun 30, 2023 | 12.19% |
| Mar 31, 2023 | 0.81% |
| Dec 31, 2022 | -10.65% |
| Jun 30, 2022 | 28.39% |
| Mar 31, 2022 | -87.76% |
| Dec 31, 2021 | -179.30% |
| Jun 30, 2021 | 15.65% |
| Mar 31, 2021 | 9.53% |
| Dec 31, 2020 | 436.51% |